Related Experiment Videos
Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study
P Federico1, D W Zochodne, A F Hahn
1Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.
Neurology
|November 23, 2000
Summary
Intravenous immunoglobulin (IVIg) significantly improved neurologic function and reduced conduction block in patients with multifocal motor neuropathy (MMN). This treatment offers a viable option for managing this rare autoimmune disorder.
Area of Science:
- Neurology
- Immunology
- Clinical Trials
Background:
- Multifocal Motor Neuropathy (MMN) is a progressive, asymmetric motor neuron disorder of likely immune origin.
- Existing evidence for Intravenous Immunoglobulin (IVIg) efficacy in MMN is based on limited studies.
- Larger, controlled trials are needed to confirm IVIg's therapeutic role in MMN.
Purpose of the Study:
- To evaluate the impact of IVIg on neurologic function and electrophysiologic parameters in MMN patients.
- To compare the effects of IVIg against placebo in a randomized, double-blind, crossover study.
Main Methods:
- 16 MMN patients participated in a randomized, double-blind, crossover trial.
- Participants received either IVIg (0.4 g/kg/day for 5 days) or placebo.
- Evaluations included functional improvement, neurologic disability, grip strength, and electrophysiologic measures like conduction block.
Main Results:
- IVIg treatment led to significant subjective functional improvement compared to placebo.
- Objective measures showed improvement in neurologic disability score and grip strength with IVIg.
- IVIg significantly improved conduction block, reversing it in five patients, while placebo worsened it.
Conclusions:
- IVIg demonstrates clear benefits in improving both clinical function and electrophysiologic measures in MMN.
- The study supports IVIg as an effective treatment for multifocal motor neuropathy.